Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123M
-
Number of holders
-
310
-
Total 13F shares, excl. options
-
95.3M
-
Shares change
-
-2.15M
-
Total reported value, excl. options
-
$1.89B
-
Value change
-
-$37.3M
-
Put/Call ratio
-
2.68
-
Number of buys
-
154
-
Number of sells
-
-125
-
Price
-
$19.88
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q3 2024
337 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q3 2024.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 310 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 95.3M shares
of 123M outstanding shares and own 77.35% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (19M shares), VANGUARD GROUP INC (8.04M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (6.23M shares), STATE STREET CORP (5.69M shares), DIMENSIONAL FUND ADVISORS LP (3.02M shares), Pacer Advisors, Inc. (2.8M shares), GEODE CAPITAL MANAGEMENT, LLC (2.66M shares), RENAISSANCE TECHNOLOGIES LLC (2.53M shares), FIRST TRUST ADVISORS LP (2.43M shares), and ROYCE & ASSOCIATES LP (2.02M shares).
This table shows the top 310 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.